51 results about "Spliceosome" patented technology

The present invention provides methods and compositions for conferring tumor selective cell death on cancer cells expressing specific target precursor messenger RNA molecules (cancer cell selective target pre-mRNAs). The compositions of the invention include conditionally replicative adenoviruses that have been genetically engineered to express one or more pre-trans-splicing molecules (PTMs) designed to interact with one or more cancer cell target pre-mRNA and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecules (chimeric RNA) capable of encoding adenovirus specific protein(s). Adenovirus specific proteins include those proteins complementing an essential activity necessary for replication of a defective adenovirus. The methods and compositions of the invention may be used to target a lytic adenovirus infection to cancer cells thereby providing a method for selective destruction of cancer cells. In addition, the adenoviruses of the invention may be engineered to encode PTMs designed to interact with target pre-mRNAs encoded by infectious agents within a cell, thereby targeting selective destruction of cells infected with such agents.

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

The invention discloses an Eriocheir sinensis EsSXL gene, an amplification primer group thereof and an amplification method. A full-length cDNA (complementary Deoxyribose Nucleic Acid) sequence of the EsSXL gene is cloned from an Eriocheir sinensis testis tissue by using the primer group provided by the invention, and the EsSXL gene comprises two variable spliceosomes EsSXL1 and EsSXL2, and lays an important foundation for the research of the important function of the function of the Eriocheir sinensis EsSXL gene in a sex differentiation process of the Eriocheir sinensis EsSXL gene.

The present invention relates to development of an animal model system for in vivo testing of spliceosome-mediated RNA trans-splicing reactions. The present invention provides transgenic animals, and methods for generating such animals, that have been genetically engineered to expresses a target precursor messenger RNA molecule (target pre-mRNA) that serves as a substrate for a trans-splicing reaction. Specifically, the transgenic animals contain at least one transgene capable of expressing a target pre-mRNA molecule. The invention provides methods, based on utilization of the transgenic animals, for assessing the specificity and efficiency of a pre-trans-splicing molecule (PTM) designed to interact with a target pre-mRNA and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule. The present invention further relates to the transgenic expression of PTM molecules in animals to determine gene function, i.e, functional genetics. The present invention is based on the successful generation of a transgenic animal expressing a target pre-mRNA and, moreover, the use of that animal to detect accurate in vivo trans-splicing reactions in the presence of a PTM.

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

The invention belongs to the technical field of biology, and particularly relates to an EZH2 variable splicing site and an application thereof. Specific siRNA is used for knocking down two subtypes ofEZH2-L and EZH2-S respectively, and myocardial hypertrophy and heart failure models are established at the cellular level and the animal level respectively. Results show that after the EZH2-L is knocked down, the expression level of a myocardial hypertrophy pathological gene is obviously reduced, the myocardial cell area is reduced, and the heart weight is reduced; and after the EZH2-S is knockeddown, the expression level of the myocardial hypertrophy pathological gene is remarkably increased, the myocardial cell area is increased, the heart weight is increased, and the situation prompts that the EZH2-L and the EZH2-S have the effects of promoting and inhibiting myocardial hypertrophy and heart failure respectively. In addition, after the EZH2-L is knocked down, tumor cell proliferationis inhibited, and knock-down of the EZH2-S has no influence on tumor cell proliferation. The invention provides a new target and a new strategy for research and development of medicines for treating EZH2 gene related diseases.

The invention discloses a MnRXR gene of macrobrachium nipponensis, and an amplification primer group and an amplification method thereof. A full-length cDAN sequence of the MnRXR gene is cloned from the hepatopancreas tissue of macrobrachium nipponensis. The gene comprises two variable spliceosomes: MnRXR-L and MnRXR-S. The invention lays an important base for research on functions of the MnRXR gene of macrobrachium nipponensis, in particularon important effects in a moult cycle.

The molecules and methods of the present invention provide a means for in vivo production of a trans-spliced molecule in a selected subset of cells. The pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The expression product of the mRNA is a protein of therapeutic value to the cell or host organism a toxin which causes killing of the specific cells or a novel protein not normally present in such cells. The invention further provides PTMs that have been genetically engineered for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to result in the production of chimeric RNA encoding for peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

The invention discloses a primer group for identifying three kinds of spliceosomes of a PML-RAR[alpha] fusion gene and a test kit and application of the primer group. The primer group for identifyingthree kinds of spliceosomes of the PML-RAR[alpha] fusion gene comprises a specific forward primer, a reverse primer, a specific fluorescent probe and a competitive primer which are used for detectingPML-RAR[alpha] fusion genes bcr1, bcr2 and bcr3 spliceosomes; according to the invention, a real-time fluorescent quantitative PCR technology is applied, multiple PCR primers and the specific fluorescent probe are adopted, and the three spliceosomes bcr1, bcr2 and bcr3 of the PML-RAR[alpha] fusion gene in a sample can be simultaneously detected in one reaction through the competitive primer; the primer group can be widely applied to multiple fields such as clinical early diagnosis, drug curative effect, after-healing monitoring and scientific research of PML-RAR[alpha] fusion gene related diseases, and has the characteristics of semi-automatic detection, high detection speed, high sensitivity and wide sample application range.

A system and method for analyzing splicing codes of spliceosomal introns is disclosed. One embodiment comprises methods of identifying introns and exons in genomic DNA or pre-mRNA sequences by locating characteristic markers in splicing junctions by computation and/or manually. Exon sequences predicted by computation can be verified and characterized by employing standard amplification methods, such as comparative genomic, RNA-seq, next-generation sequencing, RT-PCR. DNA/RNA/oligo, electrophoretic or protein chip technologies. If a given sample is verified, its polypeptide can be translated based on genetic codons. Its functions can be deduced based on its characteristics, computation predictions and related knowledge databases. These data can be used to compare databases which correlate the characterized intron or exon or gene to characterized diseases or genetic mutations. Isoforms can be detected and analyzed at mRNA and protein levels alone and with other isoforms predicted by computation, characterized by experiments and stored in existing databases.

A BMX spliceosome is provided. The nucleotide sequence of the BMX spliceosome is shown as SEQ ID NO:3. A host cell containing a gene coding the BMX spliceosome and a method of detecting functions of the BMX spliceosome by utilization of the host cell are also provided by the invention. The BMX spliceosome or the host cell containing the BMX spliceosome can be used for testing drug resistance of lung cancer cells.

The invention relates to a primer, a kit comprising the primer and a detection method for detecting a 245bp deletion alternative spliceosome of an LEPR gene and aims at solving the problems of tedious program, long consumed time and low accuracy. The detection method comprises the following steps: with cDNA as a tempelate and a primer pair ACTB as a primer, and amplifying an ACTB reference gene by virtue of real-time fluorescence quantitative PCR; with a primer pair P as a primer, carrying out real-time fluorescence quantitative PCR amplification, wherein the reaction system of the real-time fluorescence quantitative PCR amplification consists of 2*SYBR@Premix Ex TaqTMII, ultrapure water with RNase removed, a primer P-F or ACTB-F, a primer P-R or ACTB-R, and the cDNA tempelate, and the reaction method comprises the following steps: initial denaturation, denaturation, annealing and extension; and analyzing a qPCR real-time monitoring result, calculating by using 2-delta CT relative quantification, and carrying out difference significance test by SPSS version 20.0. The primer, the kit and the detection method are accurate, rapid and convenient and strong in applicability.

The invention discloses application of 3# intron retention and/or loss spliceosome LGALS3-R and/or LGALS3-M of LGALS3 in preparation of a reagent for diagnosing the acute change period of chronic myeloid leukemia or a kit containing the diagnostic reagent. The invention has relatively high sensitivity and specificity, and can observe the acute change period of chronic myeloid leukemia more simplyand accurately as soon as possible; therefore, treatment means can be adopted in time; and relatively high clinical application value is achieved.

The invention provides molecules and methods for in vivo production of a trans-spliced molecule in selected cells. Pre-trans-splicing molecules of the invention are substrates for a trans-splicing reaction between the pre-trans-splicing molecules and a pre-mRNA which is uniquely expressed in the specific target cells. The in vivo trans-splicing reaction provides a novel mRNA which is functional as mRNA or encodes a protein to be expressed in the target cells. The mRNA expression product is a therapeutic protein, a toxin which causes killing of the specific cells, or a novel protein not normally present in such cells. The invention further provides genetically engineered PTMs for the identification of exon/intron boundaries of pre-mRNA molecules using an exon tagging method. The PTMs of the invention can also be designed to produce chimeric RNA encoding peptide affinity purification tags which can be used to purify and identify proteins expressed in a specific cell type.

The invention discloses a human platelet-derived growth factor (PDGF) A homologous dimers and a high-efficiency production method thereof. The method mainly comprises the following steps: cloning a human platelet-derived growth factor A spliceosome 2 gene; constructing an eukaryotic expression vector and transferring the eukaryotic expression vector into an eukaryotic yeast host; screening a yeast transformant for high level secretion expression, wherein the PDGF-As expressed by the yeast are in a glycosylated form and a non-glycosylated form; and performing amplified culture in a shake flask, dialyzing supernate of culture solution, purifying the supernate efficiency by using a chromatography (CM) cation exchange column and G-75 molecular sieve, and obtaining the novel modified protein of the PDGF-AA dimers, of which one PDGF-A monomer is glycosylated and of which the other PDGF-A monomer is not glycosylated, by using a CM cation exchange process and optimizing the pH value of dislysate, wherein the separated and purified new glycosylation modified protein of the PDGF-AA dimers has high uniformity.

The invention discloses an application of arabidopsis thaliana MAPKKK kinase in breeding, and relates to the technical field of agricultural breeding. The breeding includes creation of the drought resistant idioplasm and early blossoming idioplasm of crucifer by a transgenic technology. The crucifer includes oilseed rape and broccoli. The MAPKKK kinase has four spliceosomes, named as AS1, AS2, AS3and AD4; an overexpression plant AS1-OE of AS1 and a mutant CRISPPAS3-2 lost by AS3 both express the non-drought resistant phenotype; AS3-OE plant and a mutant CRISPRAS1-1 lost by AS1 both express the drought resistant phenotype; AS1-OE plant and AS2/4-OE plant express the early blossoming phenotype, and AS3-OE plant expresses the late blossoming phenotype. The research can provide theoretical basis for the crucifer transgene breeding operation.

The invention discloses a primer for detecting 127bp deletion variable spliceosome of LEPR gene and a kit containing the same and a detecting method. The problems of tedious procedure, long time consumption and low accuracy can be effectively solved. The detecting method comprises the following steps: by taking a cDNA to be tested as a template and taking a primer pair ACTB as a primer, carrying out real-time fluorescence quantification PCR amplification on an ACTB reference gene; and by taking a primer pair P as a primer, carrying out real-time fluorescence quantification PCR amplification on 127bp deletion alternative spliceosome of LEPR gene, wherein the reaction system of the fluorescence quantitative PCR amplification includes ultrapure water for removing the RNA enzyme, a primer P-F or ACTB-F, a primer P-R or ACTB-R and a cDNA template, and the reaction method comprises the steps of pre-denaturing, denaturing, annealing, extending and circulating for 35-45 times, analyzing the qPCR real-time monitoring result, calculating by 2-Delta CT relative quantification method and performing SPSS version 20.0 significance test of difference. The method is accurate, rapid, convenient and strong in applicability.

The invention discloses cloning, identification and application of a salt tolerance related gene spliceosome. The method comprises the following steps: firstly, cloning two GhIRE1 gene spliceosome sequences from a salt-tolerant gene, respectively naming as GhIRE1-s1 and GhIRE1-s2, and performing prokaryotic expression by constructing a prokaryotic expression vector to obtain the GhIRE1-s1 and theGhIRE1-s2. In order to further verify the functions of the GhIRE1-s1 and the GhIRE1-s2, a GhIRE1-s1 transgenic arabidopsis thaliana plant and a GhIRE1-s2 transgenic arabidopsis thaliana plant are respectively constructed, and the stress tolerance of the GhIRE1-s1 transgenic arabidopsis thaliana plant and the stress tolerance of the GhIRE1-s2 transgenic arabidopsis thaliana plant are detected. Results show that compared with wild type arabidopsis thaliana plants, the salt tolerance of s1 transgenic arabidopsis thaliana plants is reduced. Therefore, it shows that the GhIRE1-s1 has the function of regulating and controlling the salt tolerance of the plant.

The invention discloses a human KLF7 gene promoter as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence of the human KLF7 gene promoter is selected from any one sequence as shown in SEQ ID NO: 1 to SEQ ID NO: 18; According to the invention, DNA extracted from human semen is taken as a template, 18 human KLF7 promoters are obtained by using primers for PCR amplification and restriction enzyme digestion, and test verification shows that the 18 promoters all have promoter activity in chicken preadipocytes, so that the human KLF7 gene promoter has important significance for revealing a regulation mechanism of expression of a plurality of human KLF7 transcription spliceosomes and developing drugs for targeting KLF7 expression, and lays a foundation for researching treatment of a plurality of human diseases regulated by the KLF7 gene.